multiple myaloma
Conditions
Interventions
4 cycles of IRD consolidation therapy will be administered. ixazomib 3mg at day 1,8, 15 on a 28-day cycle basis. lenalidomide 15mg at day 1-21 on a 28-day cycle basis. dexamathasone 20mg day 1, 8,
Sponsors
Tokyo-Kita Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Participants must sign the most current institutional review board (IRB)-approved informed consent form(ICF). 2) Multiple myeloma patients who received ASCT in 3 months and achieved partial response or better. 3) Age 65 - 74 years or <65 years who are not deemed appropriate for KRD consolidation therapy. 4) ECOG performance status 0-1. 5) Neutrophil >1000 and platelet >75000. 6) Serum GOT or GPT < 3.0 X upper limit of normal (ULN), and Serum total bilirubin < 1.5 ULN 7) Serum creatinine clearance > 30 ml/min.
Exclusion criteria
Exclusion criteria: 1) Peripheral neuropathy grade > 2 2) Uncontrolled diabetes. 3) Uncontrolled hypertension, arrhythmia, or heart failure. 4) Uncontrolled infectious diseases. 5) Uncontrolled psychiatric disorders. 6) Pregnant or lactating patients. 7) Allergic to ixazomib or lenalidomide. 8) Inability to comply with RevMmate. 9) Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion rate of 4 cycles of IRD consolidation therapy. | — |
Countries
Japan
Contacts
Public ContactAkira Tanimura
Tokyo-kita Medical Center Department of Hematology
Outcome results
None listed